Mirtalich (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine, and by antagonizing postsynaptic 5‑HT2 and 5‑HT3 receptors, which enhances serotonergic neurotransmission. Additional antagonism at histamine H1 receptors contributes to its sedative effect.

The dose of mirtazapine is individualized. A qualified prescriber determines the appropriate starting dose, titration schedule, and maximum daily amount based on the patient’s clinical condition, response, and tolerability. No fixed regimen is provided here.

Safety data for mirtazapine in pregnancy and lactation are limited. Clinicians must weigh potential benefits against possible risks to the fetus or infant. Use is generally reserved for situations where the therapeutic advantage justifies potential exposure, and decisions are made on a case‑by‑case basis.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from selective serotonin reuptake inhibitors (SSRIs) that primarily block serotonin reuptake. Its dual action on norepinephrine and serotonin pathways often results in a distinct side‑effect profile, such as greater sedation and appetite stimulation, which may be advantageous for patients with insomnia or weight loss.

Mirtalich should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Mirtalich is taken orally, usually once daily in the evening. It can be swallowed whole with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether to take it with meals.

Serious adverse events, although rare, include agranulocytosis (a severe drop in white blood cells), seizures, severe hypotension, and the emergence or worsening of suicidal thoughts, especially early in treatment. Prompt medical attention is required if any of these symptoms occur.

Mirtalich is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in those currently taking monoamine oxidase inhibitors (MAOIs) or who have taken an MAOI within the past 14 days. Caution is also advised for individuals with severe liver impairment or uncontrolled hypertension.